AbbVie: Arthritis, Psoriatic trials

The registry lists 36 Arthritis, Psoriatic studies with AbbVie as lead sponsor. 5 are open to participants now and 22 have results posted.

Phase 1 1Phase 2 5Phase 3 5Phase 4 1No phase 24(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisRecruitingNCT06865105Phase 2
• An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic ArthritisRecruitingNCT06764693
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingNCT06100744Phase 3
• Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved IndicationsRecruitingNCT04846959
• Expanded Access to UpadacitinibAvailableNCT04159597
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyActive, not recruitingNCT03675308Phase 3Results posted
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)CompletedNCT03671148Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)CompletedNCT03104400Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic DrugCompletedNCT03104374Phase 3Results posted
• A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)CompletedNCT02986373Phase 2Results posted
• A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)CompletedNCT02814175Phase 4Results posted
• Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)CompletedNCT02750800Results posted
• BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisCompletedNCT02719171Phase 2Results posted
• Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])CompletedNCT02414633Results posted
• A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)CompletedNCT02349451Phase 2Results posted
• To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)CompletedNCT02028169Results posted
• Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in BelgiumCompletedNCT01845818Results posted
• Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeCompletedNCT01768858Results posted
• Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic ArthritisCompletedNCT01474876Results posted
• Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab TreatmentCompletedNCT01316224Results posted
• Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With AdalimumabCompletedNCT01282372Results posted
• Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With AdalimumabCompletedNCT01273519Results posted
• Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)CompletedNCT01155570Results posted
• Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical PracticeCompletedNCT01111240Results posted
• Surveillance of Humira Injection in Korean PatientsCompletedNCT01083121Results posted
• A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )CompletedNCT01078558Results posted
• EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European CountriesCompletedNCT01078402Results posted
• An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic ArthritisCompletedNCT05616871
• A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic ArthritisCompletedNCT04758117
• A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic ArthritisCompletedNCT04541810
• Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic ArthritisCompletedNCT04433442
• Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceCompletedNCT03223012
• A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian FederationCompletedNCT02988674
• This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic ArthritisCompletedNCT02772601Phase 1
• A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197TerminatedNCT02429895Phase 2
• Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic ArthritisCompletedNCT01559038